valproic acid has been researched along with Libman-Sacks Disease in 18 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 15-year-old boy with epilepsy and cerebral calcifications, treated with valproic acid, ethyl phenylbarbiturate and ethosuximide, was referred for drug induced systemic lupus erythematosus." | 7.71 | Latent coeliac disease in a child with epilepsy, cerebral calcifications, drug-induced systemic lupus erythematosus and intestinal folic acid malabsorption associated with impairment of folic acid transport across the blood-brain barrier. ( Calvani, M; Guaitolini, C; Paolone, G; Parisi, G; Parisi, P, 2001) |
| "Valproate-induced pleural effusion is rare, but patients receiving treatment with valproic acid who develop respiratory symptoms should be examined for valproate-induced pleural effusion." | 5.12 | Clinical and pathophysiological characteristics of valproate-induced pleural effusion. ( Georgopoulou, A; Ismailos, G; Papadopoulou, E; Saroglou, M; Serasli, E; Tryfon, S; Vlachopoulos, D, 2021) |
| "A 15-year-old boy with epilepsy and cerebral calcifications, treated with valproic acid, ethyl phenylbarbiturate and ethosuximide, was referred for drug induced systemic lupus erythematosus." | 3.71 | Latent coeliac disease in a child with epilepsy, cerebral calcifications, drug-induced systemic lupus erythematosus and intestinal folic acid malabsorption associated with impairment of folic acid transport across the blood-brain barrier. ( Calvani, M; Guaitolini, C; Paolone, G; Parisi, G; Parisi, P, 2001) |
| " Following treatment with antiepileptic drugs (AEDs), the patient developed several rare complications: after beginning therapy with phenytoin, the patient developed pseudolymphoma; after monotherapy with carbamazepine (CBZ), the patient thereafter developed myoclonic jerks of upper and lower limbs upon awakening; after one year of treatment with valproate (VPA) the patient developed clinical and immuno-haematological signs of SLE." | 3.69 | Clinical case report: multiple idiosyncratic adverse effects of antiepileptic drugs in trisomy 9p. ( Diomedi, M; Gigli, GL; Masala, C; Placidi, F; Pomponi, MG; Scalise, A; Silvestri, G, 1996) |
| "Seizures were treated with valproate." | 1.31 | [Cerebral vasculitis as the initial manifestation of systemic lupus erythematosus]. ( Bergner, R; Lowitzsch, K; Niedermaier, N; Wolf, J, 2001) |
| "We treated a 31-year-old woman with systemic lupus erythematosus, renal failure with nephrotic syndrome, and a long-standing seizure disorder, who developed severe hyperammonemia with a fatal outcome." | 1.30 | Fatal hyperammonemia in a patient with systemic lupus erythematosus. ( Amano, T; Ichikawa, H; Kawabata, K; Kushiro, M; Makino, H; Nagake, Y; Wada, J, 1998) |
| " VPA dosage was tapered and discontinued, with accompanying resolution of clinical, immunological and hematological signs of SLE 6 weeks after VPA discontinuation." | 1.29 | Valproate-induced systemic lupus erythematosus in a patient with partial trisomy of chromosome 9 and epilepsy. ( Diomedi, M; Gigli, GL; Grazia Pomponi, M; Masala, C; Pauri, F; Placidi, F; Scalise, A; Silvestri, G, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 8 (44.44) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Papadopoulou, E | 2 |
| Saroglou, M | 2 |
| Ismailos, G | 2 |
| Fletsios, D | 1 |
| Tsavlis, D | 1 |
| Tryfon, S | 2 |
| Vlachopoulos, D | 1 |
| Georgopoulou, A | 1 |
| Serasli, E | 1 |
| Mohammadi, S | 1 |
| Saghaeian-Jazi, M | 1 |
| Sedighi, S | 1 |
| Memarian, A | 1 |
| Boussaadani Soubai, R | 1 |
| Lahlou, M | 1 |
| Tahiri, L | 1 |
| Rabhi, S | 1 |
| Harzy, T | 1 |
| Bono, W | 1 |
| Guzmán-Sánchez, D | 1 |
| Asz-Sigall, D | 1 |
| Sleegers, MJ | 1 |
| Beutler, JJ | 1 |
| Hardon, WJ | 1 |
| Berden, JH | 1 |
| Verhave, JC | 1 |
| Conemans, JM | 1 |
| Hollander, DA | 1 |
| Dautzenberg, PL | 1 |
| Hoogeveen, EK | 1 |
| Ozçakar, ZB | 1 |
| Yalçinkaya, F | 1 |
| Odek, C | 1 |
| Ekim, M | 1 |
| Marghescu, S | 1 |
| Neukam, D | 1 |
| Fritzler, MJ | 1 |
| Gigli, GL | 2 |
| Scalise, A | 2 |
| Pauri, F | 1 |
| Silvestri, G | 2 |
| Diomedi, M | 2 |
| Placidi, F | 2 |
| Grazia Pomponi, M | 1 |
| Masala, C | 2 |
| Himelhoch, S | 1 |
| Haller, E | 1 |
| Park-Matsumoto, YC | 1 |
| Tazawa, T | 1 |
| Pomponi, MG | 1 |
| Song, CH | 1 |
| Oftadeh, LC | 1 |
| Oh, C | 1 |
| Louie, J | 1 |
| Yu, KT | 1 |
| Ichikawa, H | 1 |
| Amano, T | 1 |
| Kawabata, K | 1 |
| Kushiro, M | 1 |
| Wada, J | 1 |
| Nagake, Y | 1 |
| Makino, H | 1 |
| Echaniz-Laguna, A | 1 |
| Thiriaux, A | 1 |
| Ruolt-Olivesi, I | 1 |
| Marescaux, C | 1 |
| Hirsch, E | 1 |
| Calvani, M | 1 |
| Parisi, P | 1 |
| Guaitolini, C | 1 |
| Parisi, G | 1 |
| Paolone, G | 1 |
| Wolf, J | 1 |
| Niedermaier, N | 1 |
| Bergner, R | 1 |
| Lowitzsch, K | 1 |
4 reviews available for valproic acid and Libman-Sacks Disease
| Article | Year |
|---|---|
Pearls for the diagnosis and possible pathophysiological mechanisms of valproic acid-induced lupus erythematosus: A literature review.
Topics: Antibodies, Antinuclear; Erythema Multiforme; Female; Humans; Lupus Erythematosus, Systemic; Male; V | 2022 |
Clinical and pathophysiological characteristics of valproate-induced pleural effusion.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Eosinophilia; Female; Humans; Lupus Erythematosus, Systemi | 2021 |
Alopecias due to drugs and other skin and systemic disorders.
Topics: Alopecia; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Dermatologic Agents; Dermat | 2015 |
Drugs recently associated with lupus syndromes.
Topics: Deferiprone; Humans; Interferon-alpha; Interleukin-2; Leuprolide; Lupus Erythematosus, Systemic; Pen | 1994 |
14 other studies available for valproic acid and Libman-Sacks Disease
| Article | Year |
|---|---|
Sodium valproate modulates immune response by alternative activation of monocyte-derived macrophages in systemic lupus erythematosus.
Topics: Cell Polarity; Cytokines; Female; Histone Deacetylase Inhibitors; Humans; Lupus Erythematosus, Syste | 2018 |
Valproate-induced systemic lupus erythematous: A case report.
Topics: Anticonvulsants; Epilepsy, Post-Traumatic; Female; Humans; Lupus Erythematosus, Systemic; Middle Age | 2013 |
Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus.
Topics: Aged; Anticonvulsants; Dementia; Diagnosis, Differential; Disease Progression; Epilepsy, Generalized | 2010 |
Oxcarbazepine and valproic acid-induced lupus in a 7-year-old boy.
Topics: Anti-Inflammatory Agents; Anticonvulsants; Carbamazepine; Child; Diagnosis, Differential; Humans; Lu | 2008 |
[Autoallergic drug exanthemas].
Topics: Autoimmune Diseases; Child; Epilepsy; Female; Humans; Lupus Erythematosus, Systemic; Male; Pemphigus | 1980 |
Valproate-induced systemic lupus erythematosus in a patient with partial trisomy of chromosome 9 and epilepsy.
Topics: Adult; Chromosomes, Human, Pair 9; Comorbidity; Epilepsy; Female; HLA-DR4 Antigen; Humans; Intellect | 1996 |
Extreme mood lability associated with systemic lupus erythematosus and stroke successfully treated with valproic acid.
Topics: Adult; Antimanic Agents; Cerebrovascular Disorders; Female; Humans; Lupus Erythematosus, Systemic; M | 1996 |
Valproate induced lupus-like syndrome.
Topics: Adolescent; Anticonvulsants; Craniocerebral Trauma; HLA-DR4 Antigen; Humans; Lupus Erythematosus, Sy | 1996 |
Clinical case report: multiple idiosyncratic adverse effects of antiepileptic drugs in trisomy 9p.
Topics: Adult; Anticonvulsants; Brain; Carbamazepine; Chromosome Aberrations; Chromosome Disorders; Chromoso | 1996 |
Successful treatment of steroid-resistant chorea associated with lupus by use of valproic acid and clonidine-HCL patch.
Topics: Administration, Oral; Adolescent; Chorea; Clonidine; Female; Humans; Injections, Intravenous; Lupus | 1997 |
Fatal hyperammonemia in a patient with systemic lupus erythematosus.
Topics: Adult; Ammonia; Anticonvulsants; Brain Diseases; Fatal Outcome; Female; Humans; Kidney Failure, Chro | 1998 |
Lupus anticoagulant induced by the combination of valproate and lamotrigine.
Topics: Antibodies, Anticardiolipin; Anticonvulsants; Child, Preschool; Dose-Response Relationship, Drug; Dr | 1999 |
Latent coeliac disease in a child with epilepsy, cerebral calcifications, drug-induced systemic lupus erythematosus and intestinal folic acid malabsorption associated with impairment of folic acid transport across the blood-brain barrier.
Topics: Adolescent; Anticonvulsants; Biological Transport; Blood-Brain Barrier; Brain; Brain Diseases; Calci | 2001 |
[Cerebral vasculitis as the initial manifestation of systemic lupus erythematosus].
Topics: Adult; Antibodies, Antinuclear; Anticoagulants; Anticonvulsants; Biopsy; Brain; Humans; Immunosuppre | 2001 |